bluuebunny/crossref_metadata_2025_split huggingface dataset:
Maternal and neonatal outcomes of antenatal anemia in a Scottish population: a retrospective cohort study
Authors: Rukuni Ruramayi , Bhattacharya Sohinee , Murphy Michael F. , Roberts David , Stanworth Simon J. , Knight Marian 
Published: February 2016

AbstractIntroductionAntenatal anemia is a major public health problem in the UK, yet there is limited high quality evidence for associated poor clinical outcomes. The objectives of this study were to estimate the incidence and clinical outcomes of antenatal anemia in a Scottish population.Material and methodsA retrospective cohort study of 80 422 singleton pregnancies was conducted using data from the Aberdeen Maternal and Neonatal Databank between 1995 and 2012. Antenatal anemia was defined as haemoglobin ≤10 g/dl during pregnancy. Incidence was calculated with 95% confidence intervals and compared over time using a chi‐squared test for trend. Multivariable logistic regression was used to adjust for confounding variables. Results are presented as adjusted odds ratios with 95% confidence interval.ResultsThe overall incidence of antenatal anemia was 9.3 cases/100 singleton pregnancies (95% confidence interval 9.1–9.5), decreasing from 16.9/100 to 4.1/100 singleton pregnancies between 1995 and 2012 (p < 0.001). Maternal anemia was associated with antepartum hemorrhage (adjusted odds ratio 1.26, 95% confidence interval 1.17–1.36), postpartum infection (adjusted odds ratio 1.89, 95% confidence interval 1.39–2.57), transfusion (adjusted odds ratio 1.87, 95% confidence interval 1.65–2.13) and stillbirth (adjusted odds ratio 1.42, 95% confidence interval 1.04–1.94), reduced odds of postpartum hemorrhage (adjusted odds ratio 0.92, 95% confidence interval 0.86–0.98) and low birthweight (adjusted odds ratio 0.77, 95% confidence interval 0.69–0.86). No other outcomes were statistically significant.ConclusionsThis study shows the incidence of antenatal anemia is decreasing steadily within this Scottish population. However, given that anemia is a readily correctable risk factor for major causes of morbidity and mortality in the UK, further work is required to investigate appropriate preventive measures.
Automatic Control of Veno‐Venous Extracorporeal Lung Assist
Authors: Kopp Ruedger , Bensberg Ralf , Stollenwerk Andre , Arens Jutta , Grottke Oliver , Walter Marian , Rossaint Rolf 
Published: February 2016

AbstractVeno‐venous extracorporeal lung assist (ECLA) can provide sufficient gas exchange even in most severe cases of acute respiratory distress syndrome. Commercially available systems are manually controlled, although an automatically controlled ECLA could allow individualized and continuous adaption to clinical requirements. Therefore, we developed a demonstrator with an integrated control algorithm to keep continuously measured peripheral oxygen saturation and partial pressure of carbon dioxide constant by automatically adjusting extracorporeal blood and gas flow. The “SmartECLA” system was tested in six animal experiments with increasing pulmonary hypoventilation and hypoxic inspiratory gas mixture to simulate progressive acute respiratory failure. During a cumulative evaluation time of 32 h for all experiments, automatic ECLA control resulted in a peripheral oxygen saturation ≥90% for 98% of the time with the lowest value of 82% for 15 s. Partial pressure of venous carbon dioxide was between 40 and 49 mm Hg for 97% of the time with no value <35 mm Hg or >49 mm Hg. With decreasing inspiratory oxygen concentration, extracorporeal oxygen uptake increased from 68 ± 25 to 154 ± 34 mL/min (P < 0.05), and reducing respiratory rate resulted in increasing extracorporeal carbon dioxide elimination from 71 ± 37 to 92 ± 37 mL/min (P < 0.05). The “SmartECLA” demonstrator allowed reliable automatic control of the extracorporeal circuit. Proof of concept could be demonstrated for this novel automatically controlled veno‐venous ECLA circuit.
Bed‐sharing by breastfeeding mothers: who bed‐shares and what is the relationship with breastfeeding duration?
Authors: Ball Helen L. , Howel Denise , Bryant Andy , Best Elspeth , Russell Charlotte , Ward‐Platt Martin 
Published: February 2016

AbstractAimTo explore the link between breastfeeding duration and bed‐sharing frequency among women reporting a prenatal intention to breastfeed.MethodsAbout 870 participants in a randomised breastfeeding trial, recruited at mid‐pregnancy, provided weekly snapshots of breastfeeding and bed‐sharing behaviour for 26 weeks following birth. Strength of prenatal breastfeeding intent was recorded at recruitment using Likert‐type scales.ResultsOutcomes were frequency of bed‐sharing at home for at least one hour per week, and time to cessation of breastfeeding. There were insufficient data to classify bed‐sharing pattern in 192/870 (22%) of mothers. Of the remainder, 44% (299/678) of participants ‘rarely’ or ‘never’ bed‐shared, 28% (192/678) did so ‘intermittently’ and 28% (187/678) did so ‘often’. These three groups did not differ significantly in marital status, income, infant gestational age, maternal age or delivery mode. Significantly, more participants who bed‐shared ‘often’ reported strong prenatal breastfeeding intent (70% vs. 57% and 56% for ‘intermittent’ and ‘rare’ bed‐share groups) and attached high prenatal importance to breastfeeding (95% vs. 87% and 82%). Significantly, more women who bed‐shared frequently were breastfeeding at 6 months (p < 0.0001) than those who intermittently or rarely/never bed‐shared.ConclusionWomen with strong motivation to breastfeed frequently bed‐share. Given the complex relationship between bed‐sharing and sudden infant death syndrome (SIDS) appropriate guidance balancing risk minimisation with support for breastfeeding mothers is crucial.
Time trends in upper gastrointestinal diseases and Helicobacter pylori infection in a multiracial Asian population – a 20‐year experience over three time periods
Authors: Leow A. H.‐R. , Lim Y.‐Y. , Liew W.‐C. , Goh K.‐L. 
Published: February 2016

SummaryBackgroundMarked epidemiological changes in upper gastrointestinal diseases and Helicobacter pylori infection have taken place in the Asian Pacific region. In particular, differences with respect to race in the multiracial Asian population in Malaysia have been important and interesting.AimA time trend study of upper gastrointestinal disease and H. pylori infection in three time periods: 1989–1990, 1999–2000 and 2009–2010 spanning a period of 20 years was carried out.MethodsConsecutive first time gastroscopies carried out on patients attending the University of Malaya Medical Center were studied. Diagnoses and H. pylori infection status were carefully recorded.ResultsA steady decline in prevalence of duodenal ulcer (DU) and gastric ulcer (GU) from 21.1% to 9.5% to 5.0% and from 11.9% to 9.4% to 9.9% while an increase in erosive oesophagitis (EO) from 2.0% to 8.4% to 9.5% (chi‐square for trend; P < 0.001) for the periods 1989–1990, 1999–200 and 2009–2010 were observed. The overall prevalence of H. pylori had also decreased from 51.7% to 30.3% to 11.1% for the same periods of time. The proportion of H. pylori positive ulcers had also decreased: DU (90.1%–69.8%–28.9%) and GU (86.6–56.8%–18.9%) (P < 0.001). This was observed in Malays, Chinese and Indians but the difference over time was most marked in Malays. There was a steady decline in the proportion of patients with gastric and oesophageal cancers.ConclusionsPeptic ulcers have declined significantly over a 20‐year period together with a decline in H. pylori infection. In contrast, a steady increase in erosive oesophagitis was observed. Gastric and oesophageal squamous cell cancers have declined to low levels.
The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience
Authors: Van Dyke Daniel L. , Werner Lillian , Rassenti Laura Z. , Neuberg Donna , Ghia Emanuella , Heerema Nyla A. , Dal Cin Paola , Dell Aquila Marie , Sreekantaiah Chandrika , Greaves Andrew W. , Kipps Thomas J. , Kay Neil E. 
Published: February 2016

SummaryThis study revisited the Dohner prognostic hierarchy in a cohort of 1585 well‐documented patients with chronic lymphocytic leukaemia. The duration of both time to first treatment (TTFT) and overall survival (OS) were significantly longer than observed previously, and this is at least partly due to improved therapeutic options. Deletion 13q remains the most favourable prognostic group with median TTFT and OS from fluorescence in situ hybridization (FISH) testing of 72 months and >12 years, respectively. Deletion 11q had the poorest median TTFT (22 months) and 17p deletion the poorest median OS (5 years). The percentages of abnormal nuclei were significantly associated with differential TTFT for the trisomy 12, 13q and 17p deletion cohorts but not for the 11q deletion cohort. From the date of the first FISH study, patients with >85% 13q deletion nuclei had a notably shorter TTFT (24 months). Patients with ≤20% 17p deletion nuclei had longer median TTFT and OS from the date of the first FISH study (44 months and 11 years), and were more likely to be IGHV mutated.
Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes
Authors: Jain Preetesh , Kantarjian Hagop , Sasaki Koji , Jabbour Elias , Dasarathula Jyothsna , Nogueras Gonzalez Graciela , Verstovsek Srdan , Borthakur Gautam , Wierda William , Kadia Tapan , Dellasala Sara , Pierce Sherry , Ravandi Farhad , O'Brien Susan , Cortes Jorge 
Published: February 2016

SummaryThis study assessed the relevance of 2013 European LeukaemiaNet (ELN) response categories on patients treated with common frontline tyrosine kinase inhibitors (TKI) in chronic myeloid leukaemia in chronic phase (CML‐CP). Four hundred and eighty‐seven patients treated with imatinib (400 mg; IM 400, n = 70; 800 mg; IM800, n = 201), dasatinib (n = 107) or nilotinib (n = 109) were analysed. Intention to treat (ITT) analysis indicated that the proportion of patients falling into optimal, warning and failure ELN categories were 89%, 6%, 6% at 3 months, 78%, 17% and 6% at 6 months, and 75%, 13% and 13% at 12 months, respectively. Rates of optimal response at 3 months were 75% for IM400, 90% for IM800, 89% for dasatinib and 97% for nilotinib; 41%, 80%, 86% and 89% at 6 months; and 47%, 77%, 76% and 87% at 12 months, respectively. Patients achieving optimal response had longer eventfree (EFS), failurefree (FFS), transformationfree (TFS) and overall survival (OS) compared to warning and failure responses at all‐time points. Treatment with imatinib 800, dasatinib or nilotinib predicted for achieving an optimal response. Optimal response predicted for significantly longer EFS, FFS, TFS and OS at 3, 6 and 12 months, irrespective of the TKI modality used. ELN response categories reliably predicted outcomes in CML patients receiving commonly used TKIs.
Effects of Poloxamer 188 on red blood cell membrane properties in sickle cell anaemia
Authors: Sandor Barbara , Marin Mickaël , Lapoumeroulie Claudine , Rabaï Miklos , Lefevre Sophie D. , Lemonne Nathalie , El Nemer Wassim , Mozar Anaïs , Français Olivier , Le Pioufle Bruno , Connes Philippe , Le Van Kim Caroline 
Published: February 2016

SummaryVaso‐occlusive crisis (VOC) is the main acute complication in sickle cell anaemia (SS) and several clinical trials are investigating different drugs to improve the clinical severity of SS patients. A phase III study is currently exploring the profit of Velopoloxamer in SS during VOCs. We analysed, in‐vitro, the effect of poloxamer (P188) on red blood cell (RBC) properties by investigating haemorheology, mechanical and adhesion functions using ektacytometry, microfluidics and dynamic adhesion approaches, respectively. We show that poloxamer significantly reduces blood viscosity, RBC aggregation and adhesion to endothelial cells, supporting the beneficial use of this molecule in SS therapy.
Predictors of early death and survival among children, adolescents and young adults with acute myeloid leukaemia in California, 1988–2011: a population‐based study
Authors: Abrahão Renata , Keogh Ruth H. , Lichtensztajn Daphne Y. , Marcos‐Gragera Rafael , Medeiros Bruno C. , Coleman Michel P. , Ribeiro Raul C. , Keegan Theresa H. M. 
Published: February 2016

SummaryA better understanding of factors associated with early death and survival among children, adolescents and young adults with acute myeloid leukaemia (AML) may guide health policy aimed at improving outcomes in these patients. We examined trends in early death and survival among 3935 patients aged 0–39 years with de novo AML in California during 1988–2011 and investigated the associations between sociodemographic and selected clinical factors and outcomes. Early death declined from 9·7% in 1988–1995 to 7·1% in 2004–2011 (P = 0·062), and survival improved substantially over time. However, 5‐year survival was still only 50% (95% confidence interval 47–53%) even in the most recent treatment period (2004–2011). Overall, the main factors associated with poor outcomes were older age at diagnosis, treatment at hospitals not affiliated with National Cancer Institute‐designated cancer centres, and black race/ethnicity. For patients diagnosed during 1996–2011, survival was lower among those who lacked health insurance compared to those with public or private insurance. We conclude that mortality after AML remained strikingly high in California and increased with age. Possible strategies to improve outcomes include wider insurance coverage and treatment at specialized cancer centres.
The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months
Authors: Lunning Matthew A. , Migliacci Jocelyn C. , Hilden Patrick , Devlin Sean M. , Castro‐Malaspina Hugo , Giralt Sergio , Perales Miguel‐Angel , Zelenetz Andrew D. , Moskowitz Craig H. , Sauter Craig S. 
Published: February 2016

SummaryEarly relapsed or refractory follicular lymphoma (FL) warrants consolidation with transplantation, though graft source modality remains controversial. We analysed the outcomes of 44 patients transplanted with either autologous or allogeneic graft sources in the post‐rituximab era. No difference in event‐free (EFS) or overall survival (OS) was observed between allogeneic (81% and 81%) and autologous transplantation (64% and 70%) at 3 years. There was a significant difference in EFS between allogeneic and autologous transplantation patients with previous remission duration of ≤12 months (80% and 42% at 3 years, P < 0·015). Very early relapsed FL may warrant consideration of allogeneic over autologous transplantation in the appropriate setting.
Spectrophotometric and visual evaluation of peri‐implant soft tissue color
Authors: Benic Goran I. , Scherrer Daniela , Sancho‐Puchades Manuel , Thoma Daniel S. , Hämmerle Christoph H. F. 
Published: February 2016

AbstractAimTo spectrophotometrically and visually test whether the peri‐implant mucosal color differs from the color of the natural gingiva.Material and methodsForty single implants in the incisor and premolar region of 40 patients were assessed 3–7 years after implant placement. The differences of the color components lightness, chroma along red‐green axis, chroma along yellow‐blue axis, and the total color difference ΔE between peri‐implant mucosa and natural gingiva were measured with a spectrophotometer. The color difference between peri‐implant mucosa and natural gingiva was visually evaluated by clinicians and rated as “clinically visible” or “clinically invisible” from speaking distance. The dimensions of peri‐implant mucosa and gingiva at the mid‐buccal aspect were evaluated by using cone‐beam CT. Spearman analysis was performed to detect correlations between different variables. Two‐sided t‐test, ANOVA, Mann–Whitney, and Kruskal–Wallis tests were applied to detect differences between the groups.ResultsThe spectrophotometrically assessed color difference ΔE between peri‐implant mucosa and natural gingiva amounted to 7.0 ± 3.9. The peri‐implant mucosa presented a significant dark, greenish and bluish discoloration in comparison with gingiva at control teeth. Clinical investigation revealed that in 60% of sites the color difference between peri‐implant mucosa and natural gingiva was clinically visible from speaking distance. The threshold value ΔE for the extraoral clinical distinction of mucosal color differences measured 7.5. When comparing the groups with visible and invisible color differences with respect to the three color components, a significant difference was found only for chroma along yellow‐blue axis. In the group with visible color difference, mucosa presented a bluish discoloration. Correlation analysis indicated that with an increase in mucosal thickness, a trend for smaller ΔE was found.ConclusionThe spectrophotometrically assessed color of the peri‐implant mucosa revealed more dark, green and blue components compared to the natural gingiva. At 60% of the implants, peri‐implant mucosal discoloration was visible from speaking distance. The sites with visible and those with invisible mucosal discolorations differed significantly only regarding the chroma along yellow‐blue axis.
Exploratory Biomarker Study of the Triple Reuptake Inhibitor SEP‐432 Compared to the Dual Reuptake Inhibitor Duloxetine in Healthy Normal Subjects
Authors: Sramek John J. , Hardy Larry W. , Bieck Peter , Zamora Cynthia , Versavel Mark , Kharidia Jahnavi , Grinnell Todd , Chen Yu‐Luan , Sullivan Michael , Ding Hong , Cutler Neal R. 
Published: February 2016

SummaryIntroductionSEP‐432 is a triple monoamine reuptake inhibitor of norepinephrine (NE), serotonin (5‐HT), and dopamine (DA), based on in vitro binding studies. We sought evidence that SEP‐432 engages these monoamine systems by measuring concentrations of monoamines and/or their main metabolites in cerebrospinal fluid (CSF) and plasma and comparing results to duloxetine, a dual reuptake inhibitor of NE and 5‐HT.MethodsEighteen healthy normal subjects received either SEP‐432 (300 mg/day), duloxetine (60 mg/day), or placebo for 14 days in‐clinic (double blind) with CSF and plasma collections at baseline (single lumbar puncture) and Day 14 (24‐h CSF and plasma collection). Concentrations of monoamines and their metabolites, as well as pharmacokinetic concentrations of SEP‐432 and metabolite, were quantified by liquid chromatography–tandem mass spectrometry.ResultsCompared to placebo in the Day 14 area under the curve 24‐h (AUC0–24 h) analysis, SEP‐432 significantly (P < 0.05) decreased the NE metabolite dihydroxyphenylglycol (DHPG) in CSF and plasma, decreased 5‐HT in plasma, and did not affect DA metabolites, while duloxetine had significant effects on DHPG and 5‐HT. Time‐matched baseline to Day 14 biomarker comparisons confirmed these findings.ConclusionCSF monoamine biomarkers confirmed central NET activity for SEP‐432 and duloxetine's dual reuptake inhibition.
Traumatic Dental Injuries in the primary dentition: a 15‐year bibliometric analysis of Dental Traumatology
Authors: Kramer Paulo Floriani , Onetto Juan , Flores Marie Therese , Borges Tássia Silvana , Feldens Carlos Alberto 
Published: February 2016

AbstractAimTo explore the profile of articles on traumatic dental injuries (TDI) in the primary dentition published in Dental Traumatology in the last 15 years using bibliometric analysis.MethodsThree researchers read all titles and abstracts of articles published in Dental Traumatology between 2000 and 2014 (excluding editorials and letters) and selected all articles on TDI in the primary dentition. The articles were categorized according to year of publication, country in which the study was conducted, study design, and topics addressed. Divergences were resolved by consensus between the researchers.ResultsAmong a total of 1257 articles published, 98 were initially excluded. Among the remaining 1159 articles, 152 (13.1%) focused on TDI in the primary dentition. The articles were conducted in 29 countries, with Brazil (38.8%) and Turkey (11.8%) accounting for the largest numbers. Cross‐sectional studies (36.2%) and case report/case series (33.6%) were the most frequent study designs. Only two systematic reviews were published. The most commonly addressed topics were frequency/etiology/associated factors (36.8%), treatment (30.9%), and prognosis (19.7%). Among the articles addressing treatment, two‐thirds were case reports or case series. The effects of TDI in primary teeth on their permanent successors were addressed in 20.4% of the articles (31/152).ConclusionsThe number of articles on TDI in the primary dentition has increased, but remains low. The evaluation of study designs and topics addressed identified gaps that could contribute to the development of new studies on TDI in the primary dentition, especially cohort studies that evaluate risk factors, prognosis, and treatment.
Minocycline added to subcutaneous interferon β‐1a in multiple sclerosis: randomized RECYCLINE study
Authors: Sørensen P. S. , Sellebjerg F. , Lycke J. , Färkkilä M. , Créange A. , Lund C. G. , Schluep M. , Frederiksen J. L. , Stenager E. , Pfleger C. , Garde E. , Kinnunen E. , Marhardt K. ,   the RECYCLINE Study Investigators
Published: February 2016

Background and purposeCombining different therapies may improve disease control in patients with relapsing−remitting multiple sclerosis (RRMS). This study assessed the efficacy and safety of minocycline added to subcutaneous (sc) interferon (IFN) β‐1a therapy.MethodsThis was a double‐blind, randomized, placebo‐controlled multicentre study. Within 3 months (±1 month) of starting sc IFN β‐1a 44 μg three times weekly, patients with RRMS were randomized to minocycline 100 mg twice daily or placebo, added to sc IFN β‐1a, for 96 weeks. The primary efficacy endpoint was the time to first qualifying relapse. Secondary efficacy endpoints were the annualized relapse rate for qualifying relapses, the number of new/enlarging T2‐weighted lesions and change in brain volume [magnetic resonance imaging (MRI) was performed only in a few selected centres]. In addition, a number of tertiary efficacy endpoints were assessed.ResultsOne hundred and forty‐nine patients received minocycline and 155 received placebo; MRI data were available for 23 and 27 patients, respectively. The time to first qualifying relapse did not differ significantly for minocycline versus placebo (hazard ratio 0.85; 95% confidence interval 0.53, 1.35; log‐rank = 0.50; P = 0.48). There were no statistically significant differences between the two groups on other efficacy endpoints, although some numerical trends in favour of minocycline were observed. No unexpected adverse events were reported, but more patients discontinued because of adverse events with minocycline versus placebo.ConclusionMinocycline showed no statistically significant beneficial effect when added to sc IFN β‐1a therapy.